Pharma News

Inflammation is an essential part of the body's healing process. But when it persists, it can contribute to a wide range of complex diseases including type 2 diabetes, heart disease, and autoimmune diseases.

Now, world-first genetic research from the University of South Australia shows a direct link between low levels of vitamin D and high levels of inflammation, providing an important biomarker to identify people at higher risk of or severity of chronic illnesses with an inflammatory component.

Scientists at Duke-NUS Medical School in Singapore have uncovered a mechanism that leads to an advanced form of fatty liver disease—and it turns out that vitamin B12 and folic acid supplements could reverse this process.

These findings could help people with non-alcoholic fatty liver disease, an umbrella term for a range of liver conditions affecting people who drink little to no alcohol, which affects 25 per cent of all adults globally, and four in 10 adults in Singapore.

Applied Lab has been started by Kumar Organic Singapore Pte. Ltd. in Singapore at Science Park Road, #04-07C, The Gemini, Lobby B, by inaugurating it on 4th August 2022.

Guest of Honor during inaugural was Indian High Commissioner Mr.P.Kumaran. Lightening of candle was done by Mr. EngHeng Khoo, VP of Clariant South East Asia Pte. Ltd. 

The preliminary analysis of Adverse Drug Reaction (ADR) from the PvPI database reveals that Tacrolimus is associated with Gingival Hypertrophy.

CDSCO issues alerts against Adsorba Hemoperfusion Cartridge 300 C and Adsorba 300 C APAC due to the potential presence of particulate matter within the cartridge.

Baxter has issued a recall notice for various batches of Adsorba Hemoperfusion Cartridge 300 C and Adsorba 300 C APACdue to presence of particulate matter within the cartridge which may lead to serious adverse effects in the patients.

Medical interns from India studies adverse Events after COVID-19 Vaccine in Indian Population. The study determined the incidence of adverse events experienced by participants post-COVID-19 vaccination and compared adverse events in participants receiving Covishield and Covaxin.

There are a lot of published studies on the efficacy of these vaccines but little is known about adverse events following vaccination outside of clinical trial data.

Nevro Corp and Boston Scientific Corp announced today that they have reached a settlement in their ongoing intellectual property litigations that gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, and gives Nevro the freedom to operate using the features and capabilities embodied in its current line of products.

Upadacitinib significantly improved the signs and symptoms of non-radiographic axial spondyloarthritis compared with placebo at week 14. Upadacitinib, sold under the brand name Rinvoq by Abbvie.

Upadacitinib, a Janus kinase inhibitor, has been shown to be effective in patients with ankylosing spondylitis. Researchers aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.

Pfizer Inc and BioNTech SE announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.